ReviewNature reviews. Rheumatology2022
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management.
Review in Nature reviews. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- Article
- Pituitary involvement in ANCA-associated vasculitis: a retrospective single-center experience and literature review.Journal of endocrinological investigation · 2026Article
- Familial associations between ANCA-associated vasculitis and other immune-mediated inflammatory diseases: a case control study.Rheumatology international · 2026Article
- Advances in the Diagnosis, Treatment and Prognosis of ANCA-Associated Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2026Review
- Hemoptysis as the initial presentation of ANCA-associated vasculitis in a patient with ulcerative colitis: a case report and literature review.Clinical rheumatology · 2026Review
- Immature leukocyte and plasma-induced cell death reveal subclinical immune activation in EGPA patients in remission.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Management of Subglottic Stenosis With the "Maddern Procedure": Long Term Follow-Up Outcomes.The Laryngoscope · 2026Article
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Histological grading of tertiary lymphoid structures correlates with renal impairment and adverse outcomes in ANCA-associated glomerulonephritis.Frontiers in immunology · 2026Article
- Genetic burden across core genes of the PI3K-AKT-mTOR pathway is associated with susceptibility to microscopic polyangiitis: a Chinese cohort study.Frontiers in immunology · 2026Article
- Article
- Article
- Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis.BMC rheumatology · 2025Article
- Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS).Rheumatology international · 2025Article
- Assessment of cardiac function and left ventricular dyssynchrony in patients with ANCA-associated vasculitis using speckle-tracking echocardiography.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- Advances in the treatment of ANCA-associated vasculitis.Nature reviews. Rheumatology · 2025Review
- IgG4-related disease and other fibro-inflammatory conditions.Nature reviews. Rheumatology · 2025Review
- Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study.Rheumatology (Oxford, England) · 2025Article
- Role of 18F-FDG PET/CT in assessing systemic involvement in ANCA-associated vasculitis.Clinical and experimental medicine · 2025Article
- A 28-Year-Old Man with Stridor and Dyspnea.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), that share features of pauci-immune small-vessel vasculitis and the positivity of ANCA targeting proteinase-3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA). AAV syndromes are rare, complex diseases and their aetio-pathogenesis is mainly driven by the interaction between environmental and genetic factors. In patients with GPA and MPA, the genetic associations are stronger with ANCA specificity (PR3- versus MPO-ANCA) than with the clinical diagnosis, which, in keeping with the known clinical and prognostic differences between PR3-ANCA-positive and MPO-ANCA-positive patients, supports an ANCA-based re-classification of these disorders. EGPA is also made up of genetically distinct subsets, which can be stratified on ANCA-status (MPO ANCA-positive versus ANCA-negative); these subsets differ in clinical phenotype and possibly in their response to treatment. Interestingly, MPO-ANCA-positive patients with either MPA or EGPA have overlapping genetic determinants, thus strengthening the concept that this EGPA subset is closely related to the other AAV syndromes. The genetics of AAV provides us with essential information to understand its varied phenotype. This Review discusses the main findings of genetic association studies in AAV, their pathogenic implications and their potential effect on classification, management and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.